Literature DB >> 21757834

Immunoglobulin D-lambda type multiple myeloma presenting with FDG-PET/CT negative bone marrow involvement.

Hisanori Machida1, Tsutomu Shinohara, Hiroyuki Hino, Mitsuteru Yoshida, Nobuo Hatakeyama, Yoshio Okano, Mami Inayama, Emiko Hosokawa, Shuichi Abe, Keishi Naruse, Yoshihito Iwahara, Fumitaka Ogushi.   

Abstract

We here report a rare case of a patient with IgD-lambda-positive multiple myeloma presenting with FDG-PET/CT negative bone marrow involvement. A 72-year-old man was admitted to our hospital for evaluation of a paravertebral tumor of the chest. Thoracotomy was performed and a histopathological evaluation of resected intrathoracic tumor demonstrated a plasmacytic neoplasma. Initially we thought that this case was a solitary plasmacytoma because there were no positive findings on postoperative FDG-PET/CT. However, bone marrow aspiration study demonstrated massive infiltration of myeloma cells (72%). It is necessary to recognize that IgD-lambda type myeloma cells may not be sufficiently metabolically active to form high uptake on FDG-PET/CT.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21757834     DOI: 10.2169/internalmedicine.50.5148

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

1.  Clinical value of ¹¹C-methionine PET/CT in patients with plasma cell malignancy: comparison with ¹⁸F-FDG PET/CT.

Authors:  Yuji Nakamoto; Kensuke Kurihara; Masatoshi Nishizawa; Kouhei Yamashita; Koya Nakatani; Tadakazu Kondo; Akifumi Takaori-Kondo; Kaori Togashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-23       Impact factor: 9.236

2.  18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.

Authors:  Thibaut Cassou-Mounat; Sona Balogova; Valérie Nataf; Marie Calzada; Virginie Huchet; Khaldoun Kerrou; Jean-Yves Devaux; Mohamad Mohty; Jean-Noël Talbot; Laurent Garderet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-28       Impact factor: 9.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.